Sales and earnings (Q4 2022)
- Net revenue
- 497,4 MSEK (+95%)
- Op. EBITDA
- 120,2 MSEK (+149%)
Financial reports
Calendar
- March 30
- Swiss Nordic Bio 2023 (Zürich, Switzerland)
- April 6
- Annual Report 2022
- April 28
- Interim Report Q1 2023
Pressreleases & news
Latest presentations
Presentation of Q4 2022
”Improved profitability but not expected growth numbers. With yet another acquisition in the last quarter we have added three new members to the Swedencare family during 2022. The net revenue for the 4th quarter was 497 MSEK, which is an increase of 95% compared to Q4 2021 and it makes it our strongest quarter ever.” – Håkan Lagerberg, CEO
